InspireMD Inc. (AMEX:NSPR) is expected to report third quarter earnings results, before market open, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.18 per share from revenue of $ 0.40 million.
Looking ahead, the full year loss are expected at $ 0.87 per share on the revenues of $ 2.35 million.
Previous Quarter Performance
InspireMD Inc. reported loss for the second quarter of $ 0.20 per share, from the revenue of $ 0.31 million. The quarterly revenues down 77.04 percent compared with the same quarter last year. Wall street analysts are predicting, NSPR to report 2Q20 loss of $ 0.35 per share from revenue of $ 0.20 million. The bottom line results beat street analysts by $ 0.15 or 42.86 percent, at the same time, top line results outshined analysts by $ 0.11 million or 55.00 percent.
Stock Performance
On Friday, shares of InspireMD Inc. has traded high as $ 0.35 and has cracked $ 0.34 on the downward trend, reaching $ 0.35 with volume of 349.80 thousand shares.
According to the previous trading day, closing price of $ 0.35, representing a 25.00 % increase from the 52 week low of $ 0.28 and a 78.66 % decrease over the 52 week high of $ 1.64.
The company has a market capital of $ 11.75 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
InspireMD Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.inspiremd.com
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms.
